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Binding and Distribution Studies in the
SENCAR Mouse of Compounds
Demonstrating a Route-Dependent
Tumorigenic Effect
by Gary P. Carlson,* Anthony A. Fossa,* Mark A. Morse,*
and Patrice M. Weaver*
Previous investigators have determined that benzo(a)pyrene [B(a)P] was much more effective in causing
skin papillomas if applied topically than when administered orally in the initiation-promotion assay in
SENCAR mouse. Conversely, urethane and acrylamide caused a higher percentage of mice to develop
papillomas and induced more tumors per mouse when given orally. In an attempt to understand the reason
for this discrepancy in route dependency, 3H-benzo(a)pyrene, '4C-urethane and "4C-acrylamide were ad-
ministered as single doses orally or topically to male SENCAR mice. Distribution in skin, stomach, liver,
and lung was determined for time periods up to 48 hr. The binding ofthese compounds to DNA, RNA, and
protein in these tissues was determined 6 and 48 hr after administration. For all three compounds, high
concentrations were found in the skin following topical application, but very little material reached this
target organ following oral administration. In contrast, the internal organs generally contained more
material after oral administration. The binding of label compounds to DNA, RNA, and protein generally
reflected the distribution data, thus more compound was bound in the stomach, liver, and lung after oral
administration compared to topical application, whereas the opposite was true for the skin. This finding
was particularly evident for B(a)P. The results suggest that differences in distribution to the skin and
binding to macromolecules following oral or topical administration cannot explain the greater tumori-
genicity of urethane and acrylamide after oral administration in the SENCAR mouse.
Introduction
The initiation-promotion assay has proved to be a
promising assay for determining tumorigenicity. It has
been refined for use with the SENCAR mouse on the
basis ofthe sensitivity ofthis strain (1). After applying
the test compound to the skin followed by a promotion
schedule, papilloma formation on the skin can be quan-
tified. As more compounds have been tested using this
system, differences in tumor incidence have been ob-
served. These differences are dependent on the route
of administration as well as on the strain of mouse (2).
Bull et al. (3) found that both the percentage ofmice
developingpapillomas and the number ofpapillomas per
mouse were greater when benzo(a)pyrene was applied
topically than when administered orally. In contrast,
these authors found that the oral administration of ur-
ethane (ethylcarbamate) resulted in agreaterpapilloma
incidence and a higher proportion of animals with pap-
illomas than when the material was applied topically. A
similar finding was observed with acrylamide, which
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Table 1. Tumors in SENCAR mouse skin following oral and
topical administrations.a
Compound
Benzo(a)-
pyrene
Urethane
Acrylamideb
Dose,
Route mg/kg
Oral 10
30
100
Topical 0.01
0.10
1.00
Oral 30
100
300
Topical 30
100
300
Oral 75
150
300
Topical 75
150
300
% Animals
with tumors
20
4
24
20
56
92
24
28
68
16
24
24
30
58
75
10
28
45
No. of
tumors per
animal
0.20
0.04
0.24
0.28
1.16
13.24
0.24
0.44
1.20
0.16
0.28
0.36
0.33
1.00
1.30
0.20
0.33
0.55
aData are from Bull and Robinson (3,4).
bDivided into six applications over a 2-week period.
demonstrated greater activity when the oral route of
administration was employed (4). These results areCARLSON ET AL.
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FIGURE 1. Distribution of [3H]-benzo(a)pyrene in tissues of SENCAR mice following oral or topical administration. [3H]-Benzo(a)pyrene
(50 mg/kg, 630 ,uCi/mmole) was administered (0) orally in an emulsion or (U) topically in acetone. Values are mean ± SE for skin (A),
stomach (B), liver (C), and lung (D). Asterisks denote significant differences between routes at the same time point (p < 0.05).
summarized in Table 1, in which the cumulative papil-
loma formation at the end of 52 weeks is presented.
The purpose ofthe present studies was to determine
ifthe route differences in tumorigenicity observed with
these three compounds could be explained by differ-
ences in distribution following administration by oral
and topical routes. A second hypothesis was tested to
determine ifthe difference in sensitivity was related to
the binding of the compounds to macromolecules, prin-
cipally DNA, rather than related to simple distribu-
tional differences.
Materials and Methods
Animals
Male SENCAR mice were obtained from Harlan
Sprague-Dawley (Indianapolis, IN). They were housed
individually in stainless steel metabolism cages.
Treatment of Animals
[G-3H]Benzo(a)pyrene (Amersham Corporation, Ar-
lington Heights, IL) was diluted with unlabeled B(a)P
(Sigma Chemical Co., St. Louis, MO). It was either
administered orally viaintubation in an emulsion of10%
GAF Emulphor EL 620 and 90% water or was applied
topically in acetone. Theback ofeachanimal was shaved
36 to 48 hr before treatment, and the compound was
administered at adose of50mg/kgand aspecific activity
of 630 pCi/mmole in the distribution studies and 25.2
mCi/mmole in the binding studies. Groups of at least
five animals were sacrificed at 0.5, 1, 6, 12, 24, and 48
hr after treatment in the distribution studies and at 6
and 48 hr in the binding studies.
Ethyl-1-14C-urethane (New England Nuclear, Bos-
ton, MA) was diluted with unlabeled urethane (Sigma
Chemical Co.) and administered at a dose of 100 mg/kg
(89 ,uCi/mmole) for the distribution studies and 62 mg/
kg (3.59 mCi/mmole) forthe binding studies. Water was
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used as the vehicle for the oral studies and acetone for
the topical. Observations were made at similar times
starting at 1 hr. [2,3-14C]-Acrylamide (New England
Nuclear, Boston, MA, for the distribution studies and
Pathfinder Laboratories, St. Louis, MO, for the binding
studies) was diluted with unlabeled acrylamide (Be-
thesda Research Laboratories, Gaithersburg, MD) and
administered at a dose of 100 mg/kg with a specific ac-
tivity of56.9 ,uCiImmole for the distribution studies and
1.185mCilmmole forthe binding studies. The compound
was administered in water orally or in ethanol topically.
Groups of mice were sacrificed starting at 15 min after
administration of the compound.
Treatment of Tissues in Distribution
Studies
Duplicate 50 to 100 mg portions of skin, liver, lung,
and stomach were obtained. In the acrylamide studies,
testes were also removed. The tissues were minced and
digested in 1.0 mL NCS tissue solubilizer (Amersham
FIGURE 2. Binding of[3H]-benzo(a)pyrene to DNA, RNA, and pro-
tein in tissues of SENCAR mice 6 and 48 hr following oral or
topical administration. [3H]-Benzo(a)pyrene (50 mg/kg, 25.2 mCi/
mmole) was administered orally in an emulsion (hatched bars) or
topically inacetone (solid bars). Valuesaremean ± standard error
(SE). Asterisks denote significant differences between routes at
the same time point for the same tissue (p < 0.05).
Corporation) for 24 hr at 500C. Afterdissolution, 10 mL
ofAquasol II (New England Nuclear) were added, and
the samples were counted in a liquid scintillation spec-
trometer. [14C]-toluene and [3H]-toluene were added as
internal standards and the samples recounted.
Isolation and Analysis of Macromolecules
Intheurethanestudies, portionsofthe skin, stomach,
liver, and lungs were removed and homogenized in an
aqueous solution (1% NaCl, 1% triisopropylnaphthalene
sulfonic acid, 6% sec-butyl alcohol and 6% p-aminosali-
cylate). Skin was frozeninliquid nitrogen and shattered
before homogenization. Tissues including the testes
were similarly treated in the acrylamide studies. In the
B(a)P experiments, the epidermallayers were removed
by a thermal method (5) and homogenized with a Po-
lytron PT-10.
The DNA, RNA, and protein were isolated using a
modification of the methods of Kirby and Cook (6) and
Marmur (7). An equal volume ofchloroform/isoamyl al-
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FIGURE 3. Distribution of ['4C]-urethane in tissues of SENCAR mice following oral or topical administration. ['4C]-Urethane (100 mg/kg,
89 ,uCi/mmole) was administered (@) orally in water or (U) topically in acetone. Values are mean ± SE for skin (A), stomach (B), liver
(C), and lung (D). Asterisks denote significant differences between routes at the same time point (p < 0.05).
cohol (24:1) was added tothe aqueousphase. Aftershak-
ing and centrifuging, the aqueous layer containing the
RNA and DNA was removed, washed with the same
solution, and recentrifuged. The DNA was precipitated
with ethoxyethanol and the RNA with ethanol and cool-
ing. The epidermal samples were treated with protease
K and solubilized in NCS solution. Aquasol II was then
added. The samples were counted as in the distribution
studies. Protein fromthe interface was quantified using
the Lowry procedure (8).
Data Expression and Analysis
Since no attempt was made to differentiate between
parent compound and metabolites or to identify the la-
beled material bound, data are expressed as equiva-
lents. Differences between the two routes were ana-
lyzedusingStudent's t-testattheindividualtimepoints.
A p value of 0.05 was selected to represent statistical
significance.
Results
When B(a)P was administered topically, the concen-
tration in the skin peaked at 1 hr (Fig. 1). By 6 hr, the
concentrationhadrapidlydeclined, and labeled material
was slowly lost from the skin afterthat time. Very little
material reached the skin when it was administered
orally. In contrast, only small amounts of B(a)P were
found in the stomach tissue when the compound was
given topically compared to that found soon after oral
administration, although little difference between the
two routes was observed after 12 hr. Similar findings
were observed in the liver and lung.
More B(a)P was bound to the DNA ofthe liver, lung,
and stomach in the orally treated animals than in the
topically treated animals at both 6 and 48 hr (Fig 2).
However, the amount oflabeledmaterialboundto DNA
after topical application was greater in the skin (epi-
dermis) than in other tissues and was much higher than
that observed after oral administration. Similar differ-
ences were exhibited in RNA and protein.
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When urethane was applied to the backs ofthe SEN-
CAR mice, the concentrations found in the skin were
many times higher than those found after oral admin-
istration (Fig. 3). The decline with time was quite slow.
In contrast, the concentration oflabeled material found
in the stomach tissue was quite low after topical appli-
cation and was less than that seen after oral adminis-
tration at all time points. The liver and lungs displayed
a similar pattern and level, as did the stomach, sug-
gesting a fairly even distribution of urethane among
these internal organs.
When the binding ofthe ['4C] to DNA wasmeasured,
the differences between the routes of administration
were not as great as those observed in the distribution
studies (Fig. 4). No significant differences were ob-
served at the 6-hr time point. However at 48 hr, more
labeled material was bound to DNA in the stomach and
liver ofthe orally treated animals and in the skin ofthe
topically treated animals. The pattern of binding to
RNA was quite similar, except that there was no dif-
ference in the pattern of binding to RNA in the skin
FIGURE 4. Binding of ['4C]-urethane to DNA, RNA and protein in
tissues of SENCAR mice 6 and 48 hr after oral or topical admin-
istration. ['4C]-Urethane (62 mg/kg, 3.59 mCi/mmole) was admin-
istered orally in water (hatched bars) or topically in acetone (solid
bars). Values are mean + SE. Asterisks denote significant dif-
ferences between routes atthe same time pointforthe same tissue
(p < 0.05).
between the two routes. The binding of urethane to
proteinwasgreaterinthe stomach 6hrafteroraladmin-
istration and was greater in the skin 6 and 48 hr after
topical application.
Although high concentrations of ['4C]-acrylamide
were present in the skin following topical application,
very little was present in this tissue after oral admin-
istration (Fig. 5). Surprisingly highconcentrations were
observed in the stomach after topical application, but
these decreased rapidly and from 6 to 24 hr, were lower
than those measured in the orally treated animals. In
liver, lung, and testes, concentrations peaked 30 to 60
min after treatment by either route and then sharply
declined. In general, the oral treatment resulted in
higher concentrations of acrylamide in the tissues
through 24 hr, but by 48 hr, there were no differences
between the groups.
The distribution data were reflected in the binding of
acrylamide to macromolecules (Fig. 6). Binding to
DNA, RNA, and protein in the internal organs was
elevated in the orally treated mice compared to that in
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FIGURE 5. Distribution of['4C]-acrylamide in tissues of SENCAR mice following oral or topical administration. ['4C]-Acrylamide (100 mg/
kg, 56.9 i±Ci/mmole) was adminstered (0) orally in water or (U) topically in ethanol. Values are mean + SE for skin (A), stomach (B),
liver (C), lung (D), and testes (E). Asterisks denote significant differences between routes at the same time point (p < 0.05).
the topically treated animals, whereas the opposite was
true for the skin.
Discussion
B(a)Pisawellestablished carcinogen. Althoughmuch
less potent, urethane has been demonstrated to cause
tumors in the lung (9,10), liver (11,12), stomach (13),
and skin (14,15). Acrylamide causes skin papillomas in
the SENCAR mouse and lung adenomas in the A/J
mouse (4) and is structurally related to vinyl carbamate
hypothesized as the active metabolite ofurethane (16).
The purpose ofthe current studies was to attempt to
explain the differences in the incidence of skin papillo-
mas in SENCAR mice. Bull et al. (3,4; personal com-
munication) found that B(a)P caused many more tumors
when administered topically, whereas both urethane
andacrylamide were moretumorigenicbythe oralroute
(Table 1). One possibility was that urethane and acry-
lamide, which are much more hydrophilic than B(a)P,
did not penetrate the skin well and that higher concen-
trations were achieved in this tissue after oral admin-
istration due to delivery of the material to this tissue
via the blood. The data, however, did not support this
hypothesis. Rather these two compounds resembled
B(a)P in that higher concentrations of labeled material
were found in the skin after topical application than
after oral treatment.
A second possibility was examined. It was possible
that the urethane and acrylamide were activated by the
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liver and/or other organs to proximate carcinogens,
which were subsequently transported to the target or-
gan, the skin. This hypothesis, which was examined by
determining the degree of binding to macromolecules,
also does not appear to be supported by our data. Al-
though the differences were not as striking as those
found with B(a)P, in general, the binding of the ure-
thane and acrylamide to DNA, RNA, and protein was
greater in the internal organs following oral adminis-
tration and was greater in the skin following topical
application. Thus neither the distribution nor the bind-
ing data can adequately explain the route differences in
the induction ofpapillomas in SENCAR mice. Further
studies are necessary to evaluate athird possibility that
there are differences in the DNA adducts formed fol-
lowing the administration ofthe compounds by the two
routes.
This study was supported in part by NIH National Research Serv-
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FIGURE 6. Binding of ['4C]-acrylamide to DNA, RNA and protein
in tissues ofSENCAR mice 6 and 48 hr after oral or topical admin-
istration. ['4C]-Acrylamide (100 mg/kg, 1.185 mCilmmole) was ad-
ministered orally in water (hatched bars) or topically in ethanol
(solid bars). Values are mean ± SE. Asterisks denote significant
differences between routes at the same time point for the same
tissue (p < 0.05).
approved for publication as an EPA document. Mention of trade
names or commercial products does not constitute endorsement or
recommendation for use.
REFERENCES
1. DiGiovanni, J., Slaga, T. J., and Boutwell, R. K. Comparison of
the tumor-initiating activity of 7,12-dimethylbenz(a)anthracene
and benzo(a)pyrene in female SENCAR and CD-1 mice. Carcin-
ogenesis 1: 381-389 (1980).
2. Slaga, T. J., Fischer, S. M., Weeks, C. E., Klein-Szanto, A. S.
P., and Reiners, J. Studies on the mechanism involved in the
multistage carcinogenesis in mouse skin. J. Cell. Biochem. 18:
99-119 (1982).
3. Bull, R. J., Robinson, MA, Glass, J., Omehil, D., and Orthoefer,
J. Induction of skin papiIlomas in the SENCAR mouse as a tier
2 carcinogenesis bioassay. Toxicologist 1: 129-130 (1981).
4. Bull, R. J., Robinson, M., Laurie, R. D., Stoner, G. D., Greisiger,
E., Meier,J. R., and Stober,J. Carcinogenic effects ofacrylamide
in SENCAR and A/J mice. Cancer Res. 44: 107-111 (1984).
5. Slaga, T. J., Das, S. B., Rice, J. M., and Thompson, S. Frac-
tionation of mouse epidermal chromatin components. J. Invest.
Dermatol. 63: 343-349 (1974).
6. Kirby, K. S., and Cook, E. A. Isolation ofdeoxyribonucleic acid
from mammalian tissues. Biochem. J. 104: 254-257 (1967).60 CARLSON ET AL.
7. Marmur, J. A procedure forthe isolation ofdeoxyribonucleic acid
from microorganisms. Methods Enzymol. 6: 726-738 (1963).
8. Lowry, 0. H., Rosebrough, N. J., Farr, A. L., and Randall, R.
J. Protein measurement with Folin reagent. J. Biol. Chem. 193:
265-271 (1951).
9. Nettleship, A., Henshaw, P., and Meyer, H. Induction of pul-
monary tumors in mice with ethyl carbamate (urethane). J. Natl.
Cancer Inst. 4: 309-319 (1943).
10. Yamamoto, R. S., Weisburger, J. H., and Weisburger, E. K.
Controlling factors in urethane carcinogenesis in mice; effect of
enzyme inducers and metabolic inhibitors. Cancer Res. 31: 483-
486 (1971).
11. Heston, W. E., Vlahakis, G., and Deringer, M. K. Highincidence
ofspontaneous hepatomas and the increase ofthis incidence with
urethane in C3H, C3Hf and C3He male mice. J. Natl. Cancer
Inst. 24: 425-435 (1960).
12. Klein, M. Influence of age on induction of hepatomas and other
tumors in infant mice. J. Natl. Cancer Inst. 36: 1111-1120 (1966).
13. Berenblum, I., and Haran-Ghera, H. Papilloma formation in the
forestomach of the mouse following oral administration of ure-
thane (ethyl carbamate). Cancer Res. 17: 329-331 (1957).
14. Salaman, M. H., and Roe, F. J. C. Incomplete carcinogens: Ethyl
carbamate (urethane) as an initiator of skin tumour formation in
the mouse. Brit. J. Cancer 7: 472-481 (1953).
15. Pound, A. W., and Bell, J. R. The influence of croton oil stimu-
lation of tumour initiation by urethane in mice. Brit. J. Cancer
16: 690-695 (1962).
16. Dahl, G. A., Miller, J. A., and Miller, E. C. Vinyl carbamate as
apromutagen and amore carcinogenic analogofethyl carbamate.
Cancer Res. 38: 3793-3804 (1978).